Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple
clinical conditions and may be associated with a variety of cardiovascular and respiratory …

2022 ESC/ERS pulmonary hypertension guidelines incorporate changes and adaptations
focusing on clinical management https://bit. ly/3QtUvb4

Background Pulmonary arterial hypertension is a progressive, fatal disease. Published
treatment guidelines recommend treatment escalation on the basis of regular patient …

Background Achievement of low-risk status is a treatment goal in pulmonary arterial
hypertension (PAH). Risk assessment often is performed using multiparameter tools, such …

Abstract Purpose of Review Pulmonary arterial hypertension (PAH) is a chronic,
progressive, and incurable disease with significant morbidity and mortality. Despite …

Erratum: 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension:
Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the …

Aim Pulmonary hypertension (PH) is a rare, severe, and progressive pulmonary vascular
disease, which includes five subgroups with similar presentation. Symptoms include …

Performing longitudinal and consistent risk assessments for patients with pulmonary arterial
hypertension (PAH) is important to help guide treatment decisions to achieve early on and …

Background Pulmonary arterial (PA) stiffness has an essential contribution to the right
ventricular (RV) failure pathogenesis. A comprehensive and multiparameter risk assessment …

Treatment of pulmonary arterial hypertension (PAH) has come a long way in the last two
decades. We have improved functional status and survival, developed new therapies, begun …